CHINARES PHARMA(03320): In 2025, Jiangzhong Pharmaceutical achieved a net profit attributable to the parent company of 9.06 billion yuan, a year-on-year increase of 14.96%.

CHINARES PHARMA (03320) announced that in 2025, Jiangzhong Pharmaceutical achieved operating income of 4.22 billion yuan, a year-on-year decrease of 4.87%, and net profit attributable to shareholders of the listed company of 906 million yuan, a year-on-year increase of 14.96%. During the reporting period, faced with industry structural adjustment pressure, Jiangzhong Pharmaceutical continued to strengthen brand building, focusing on "major single products, strong product categories" to solidify the foundation of its core business. In addition, Jiangzhong Pharmaceutical enriched its marketing strategies, strengthened investment returns, optimized cost structures, deepened lean manufacturing, promoted cost reduction and efficiency improvement, and helped increase profitability levels.